Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the potential role of JAK inhibitors, like ruxolitinib, as emerging therapeutic agents in dermatology, but reports no new clinical results.

This review discusses cutaneous extramedullary haematopoiesis and its potential mechanisms but reports no new clinical findings.

This article reports a case of macular amyloidosis associated with myelofibrosis with myeloid metaplasia, a combination not previously documented.

This study reported that topical drugs regrew hair in mice.

This review discusses the approved uses and adverse reactions of JAK inhibitors, noting their importance in treating various conditions but highlighting significant hematological and immunological risks.

This case report discusses two female patients experiencing significant hair loss, potentially linked to a weight loss regimen involving chorionic gonadotropin injections.

This letter to the editor describes two cases where stopping tetracycline treatment coincided with the disappearance of multiple flat warts on the face in young women.

This case study reported significant but temporary hair regrowth and skin repigmentation in a patient with vitiligo and alopecia areata during treatment with oral ruxolitinib.

This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.

This systematic review found that Janus kinase inhibitors have shown beneficial effects for psoriasis and alopecia areata, with promising preliminary results in other skin conditions, though more research is needed to define dosing and safety profiles.

This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.

This research highlights that JAK inhibitors, such as baricitinib, may effectively reverse symptoms of alopecia areata by targeting specific immune pathways, though safety and efficacy require further investigation.

This study reports the first case of eyelash elongation and thickening in a patient with hypereosinophilic syndrome taking the Janus kinase inhibitor ruxolitinib.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

This case study suggests a possible rare follicular variant of neutrophilic dermatosis linked to myelogenous leukemia, where skin lesions improved following chemotherapy treatment.

Mycophenolate mofetil improved skin condition in a man with nephrogenic fibrosing dermopathy.

This review discusses the role of stem cell progeny as integral components of stem cell niches, offering feedback that may influence different stem cell systems' microenvironments, but it presents no new research findings.

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.

This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.

This study observed that applying JAK-STAT pathway inhibitors to mouse and human skin led to rapid hair growth by inducing the anagen phase of hair follicles.

This consensus statement outlines a treatment algorithm for alopecia areata, discussing when to consider systemic treatment and how to assess outcomes, without providing new clinical results.

This review discusses the roles of αβ and γδ T cells in skin health and disease and reports no new clinical results; the authors highlight potential therapeutic developments.

This review discusses the JAK-STAT pathway and the use of FDA-approved JAK inhibitors for autoimmune and inflammatory diseases but reports no new research findings.

This review discusses the efficacy and safety of topical JAK inhibitors for inflammatory skin conditions, reporting modest benefits in psoriasis and atopic dermatitis but mixed results for vitiligo and inconclusive data for alopecia areata.

This review found that JAK/STAT pathway inhibitors, such as tofacitinib and ruxolitinib, led to symptom improvement in all observed atopic dermatitis cases, but responses were mixed for vitiligo and alopecia areata, with a generally mild safety profile reported.

This study found that impaired autophagy plays a role in sonic hedgehog pathway-induced endometrial fibrosis, suggesting it as a potential target for treating intrauterine adhesion.

This review discusses emerging treatments and mechanisms for alopecia, highlighting potential therapies like janus kinase inhibitors and advances in stem-cell technology, but reports no new experimental results.

Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.